GSK1070806: Clinical Trials

5 completed, 3 terminated, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 6 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	6	Completed 4, Not yet recruiting 1, Recruiting 1
Phase 2	6	Terminated 3, Completed 2, Unknown 1

Follow GSK1070806: new trials by email Literature Review of GSK1070806 trials Research Report on GSK1070806

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative Colitis Aletekitug (GSK1070806) - Colitis, Ulcerative	Phase 1	Recruiting	GlaxoSmithKline	8	2026-09-03	2026-10-28
A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis Aletekitug - Colitis, Ulcerative	Phase 1	Not yet recruiting	GlaxoSmithKline	16	2026-08-10	2026-08-05
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. GSK1070806, Placebo - Dermatitis, Atopic	Phase 2	Terminated	GlaxoSmithKline	79	2024-06-05	2026-06-16
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis GSK1070806, Placebo - Dermatitis, Atopic	Phase 2	Terminated	GlaxoSmithKline	161	2023-11-16	2026-06-03
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive GSK1070806, Placebo - Dermatitis, Atopic	Phase 1	Completed	GlaxoSmithKline	38	2022-11-04	2024-08-13
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis GSK1070806, Placebo - Dermatitis, Atopic	Phase 1	Completed	GlaxoSmithKline	34	2021-11-18	2025-08-28
A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease GSK1070806, Placebo- sodium chloride - Crohn Disease	Phase 1 / Phase 2	Completed	University of Birmingham	5	2019-02-20	2021-04-28
Anti IL-18 (GSK1070806) in Behcet's Disease GSK1070806 - Behcet's Disease	Phase 2	Unknown	Cambridge University Hospitals NHS Foundation Trust	12	2018-08-01	2018-05-11
Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation GSK1070806, 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids - Kidney Transplantation (Status Post)	Phase 2	Terminated	GlaxoSmithKline	7	2016-08-27	2019-06-26
Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM GSK1070806, Placebo (saline) - Diabetes Mellitus	Phase 2	Completed	GlaxoSmithKline	37	2012-08-01	2016-11-21
First Time in Human Study of Intravenous Interleukin-18 Antibody GSK1070806 - Inflammatory Bowel Diseases	Phase 1	Completed	GlaxoSmithKline	78	2010-01-05	2017-06-12

Conditions studied

Dermatitis, Atopic (4)  ·  Inflammatory Bowel Diseases (3)  ·  Colitis, Ulcerative (2)  ·  Dermatitis (2)  ·  Eczema (2)  ·  Gastrointestinal Diseases (2)  ·  Immune System Diseases (2)  ·  Behcet Syndrome (1)  ·  Crohn Disease (1)  ·  Delayed Graft Function (1)  ·  Diabetes Mellitus (1)  ·  Obesity (1)  ·  Skin Diseases (1)

Sponsors

GlaxoSmithKline (9)  ·  Cambridge University Hospitals NHS Foundation Trust (1)  ·  University of Birmingham (1)

Countries

United Kingdom (6)  ·  Spain (4)  ·  United States (4)  ·  Canada (3)  ·  Argentina (2)  ·  Bulgaria (2)  ·  China (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Greece (2)  ·  Japan (2)  ·  Mexico (2)  ·  Panama (2)  ·  Poland (2)

Top investigators

Marietta Iacucci, MD,PhD (1)  ·  Rona M Smith, MD MRCP (1)

Results publications

PMID 25109413, PMID 26930607, PMID 33684160

NIH funding

2023 (2), 2015 (1), 2018 (1)